Westport, CT - June 15, 2017
Intensity Therapeutics, Inc., a privately held clinical-stage, biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office (PTO) issued the Company patent 9,636,406. In addition, the Company noted that the Australian PTO intends to grant Intensity patent 2013318338.
Westport, CT - May 30, 2017
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the first patient successfully received treatment with the Company’s lead product, INT230-6, as part of a Phase 1/2 international clinical study. Initiation of the study followed acceptance of an investigational new drug (IND) submission by the US Food and Drug Administration’s Division of Oncology Products 1 (DOP1) and receipt from Health Canada of a No Objection Letter following submission of a clinical trial application (CTA). The clinical trial, IT-01 (NCT#03058289), entitled A Phase 1/2 Safety Study of Intratumorally Administered INT230-6 in Adult Subjects with Advanced Refractory Cancers, aims to enroll approximately 60 patients with several different types of advanced solid tumors.
Westport, CT - June 28, 2016
Intensity Therapeutics, Inc. raises $10 million in its Series A round to fund Phase I/II human clinical trials for its novel cancer treatment; adds two board members.
Westport, CT - June 2, 2016
Intensity Therapeutics, Inc., a privately held biotechnology company developing proprietary cancer immunotherapy products, today announced that the United States Patent and Trademark Office issued the Company US Patent 9,351,997, which protects Intensity's lead product INT230-6.
Westport, CT - Business Wire - April 19, 2016
Chief Medical Officer Dr. Ian B Walters presents the mechanism of action of Intensity Therapeutics products and other data in a poster session at the American Academy of Cancer Research (AACR) meeting today, showing that INT230-6 induces significant cancer cell death in the tumor microenvironment. Thereafter, eradication of the tumor by INT230-6 requires T lymphocytes and leads to a potent and durable systemic anti-cancer T-cell-dependent immunity against the tumor.
By John Pletz, Crain's Chicago Business, April 9, 2016
Cleversafe raised $100 million, mostly from Chicago investors, including those participating in Batterson Venture Capital's Series A investment. Chris Gladwin estimates the sale of Cleversafe created about 80 millionaires.
News Release, March 8, 2016
Intensity Therapeutics has been selected to present at the 23rd annual Future Leaders in the Biotech Industry conference hosted by BioCentury. CEO Lewis Bender will present an update on the Company and the development status of INT230-6, an immune cell-activating, anti-cancer drug candidate.
News Release, March 3, 2016
Pre-clinical research from Intensity and its collaborators at the National Cancer Institute
(NCI) were selected for oral presentation at two important upcoming congresses.
News Release, Nov. 6, 2015
IBM completes the acquisition of Cleversafe. Batterson Venture Capital was an early stage (Series A) investor in the company.
News Release, Oct. 22, 2015
Douglas Hanahan, Riccardo Lencioni and Mario Sznol join Intensity Therapeutics' newly formed Scientific Advisory Board (SAB). These world-renowned scientists and physicians will provide research and development guidance on Intensity’s proprietary products and technology. The SAB members span a broad range of expertise relevant to Intensity’s approach including: immuno-oncology, clinical trial design, interventional oncology, tumor imaging, tumor microenvironment, cell regulation and cancer vaccination.
News Release Issued by IBM, Oct 5, 2015
IBM has entered into a definitive agreement to acquire Cleversafe, Inc. Batterson Venture Capital was an early stage (Series A) investor in the company.
by John Peltz, Crain's Chicago Business, 18 Sept 2015
At the Illinois Technology Association's CityLights Awards honoring 8 Chicago companies, technologists and entrepreneurs, CEO of the year was awarded to John A. Morris of Cleversafe. ITA is a trade association for growth-stage tech firms.
by John Pletz, Crain's Chicago Business, 21 July 2015
VCapital is raising money online to help Intensity Therapeutics, Inc advance its cancer-reversing technology to human trials.
by Steve Hendershot, Crain's Chicago Business, 14 July 2015
Meet Cleversafe's Jason Resch, the kind of man you build a company around, in this brief profile leading up to Crain's full reveal of Chicago's TECH 50.
iRODS Consortium, 12 May 2015
Cleversafe, the market share leader in web-scale data storage, will become the ninth member of the iRODS Consortium, a membership-based foundation organized to sustain the integrated Rule-Oriented Data System (iRODS) as free open source data management software.
by John Pletz, Crain's Chicago Business, 19 March 2015
By now, it's no secret that Chicago and Illinois companies had a very good year in 2014 when it comes to venture funding.
More data continue to trickle in, this time from PricewaterhouseCoopers and the National Venture Capital Association.
Cleversafe, Wednesday, 04 March 2015
Cleversafe Inc., the web-scale storage market share leader, today announced its new partnership with Ericsson as the data storage platform provider
Intensity Therapeutics, Inc (pdf), 3 March 2015
Intensity Therapeutics, Inc. (private), developing novel cancer immunotherapy products, announced that President and CEO Lewis H. Bender will present at the 7th Annual Biotech Showcase & Investor Conference
Cleversafe, Wednesday, 05 January 2015
Cleversafe Inc., the industry-leading object-based storage provider, was named a Leader in the IDC MarketScape: Worldwide Object-Based Storage 2014 Vendor Assessment